----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/Projects/cortellis_projects/clinical_trials/reports/report_01-18-18/regs/regression_output_01-18-18.log
  log type:  text
 opened on:  18 Jan 2018, 10:13:30

. 
. label variable any_public "Public firm (lower bound)"

. label variable any_public_max "Public firm (upper bound)"

. 
. * ------------------------------*
. * Main LPM regressions (Table 9)
. * ------------------------------*
. lpm_regs, lpm(g_lpm) estimator(regress) quietly 
Dependent variable: g_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0038*  &      0.0038*  &      0.0038*  &      0.0038*  &      0.0050   &      0.0050   &      0.0050   &      0.0050   \\
                    &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0024)   &    (0.0024)   &    (0.0024)   &    (0.0024)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0097   &      0.0099   &      0.0097   &      0.0100   &      0.0124   &      0.0127   &      0.0129   &      0.0131   \\
                    &    (0.0095)   &    (0.0095)   &    (0.0093)   &    (0.0094)   &    (0.0109)   &    (0.0110)   &    (0.0107)   &    (0.0107)   \\
Phase 3 Clinical    &      0.0167   &      0.0164   &      0.0168   &      0.0165   &      0.0190   &      0.0188   &      0.0195   &      0.0193   \\
                    &    (0.0146)   &    (0.0145)   &    (0.0143)   &    (0.0143)   &    (0.0160)   &    (0.0159)   &    (0.0158)   &    (0.0157)   \\
Trial site in US=1  &      0.0134***&      0.0127***&      0.0125** &      0.0118** &      0.0138***&      0.0130***&      0.0090*  &      0.0082*  \\
                    &    (0.0021)   &    (0.0023)   &    (0.0032)   &    (0.0032)   &    (0.0027)   &    (0.0029)   &    (0.0036)   &    (0.0036)   \\
Drug indication for neoplasm=1&      0.1374***&      0.1376***&      0.1363***&      0.1364***&      0.1504***&      0.1504***&      0.1443***&      0.1443***\\
                    &    (0.0148)   &    (0.0148)   &    (0.0120)   &    (0.0120)   &    (0.0186)   &    (0.0186)   &    (0.0133)   &    (0.0133)   \\
Biomarker type: genomic=1&      0.2429*  &      0.2429*  &      0.2428*  &      0.2428*  &      0.2403*  &      0.2403*  &      0.2398*  &      0.2398*  \\
                    &    (0.1103)   &    (0.1103)   &    (0.1105)   &    (0.1104)   &    (0.1128)   &    (0.1128)   &    (0.1131)   &    (0.1131)   \\
Public firm (lower bound)&      0.0104*  &               &      0.0104*  &               &      0.0129*  &               &      0.0129*  &               \\
                    &    (0.0044)   &               &    (0.0044)   &               &    (0.0061)   &               &    (0.0061)   &               \\
Public firm (upper bound)&               &      0.0117*  &               &      0.0117*  &               &      0.0136*  &               &      0.0135*  \\
                    &               &    (0.0049)   &               &    (0.0049)   &               &    (0.0063)   &               &    (0.0063)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0024   &      0.0025   &               &               &      0.0142   &      0.0142 
>   \\
                    &               &               &    (0.0077)   &    (0.0076)   &               &               &    (0.0133)   &    (0.0133)   \\
Constant            &     -7.6404*  &     -7.6590*  &     -7.6465*  &     -7.6654*  &    -10.0729   &    -10.1599   &    -10.0572   &    -10.1441   \\
                    &    (2.8601)   &    (2.8172)   &    (2.8436)   &    (2.8008)   &    (4.8924)   &    (4.8829)   &    (4.9004)   &    (4.8911)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       92568   &       92568   &       92568   \\
r2                  &       0.271   &       0.271   &       0.271   &       0.271   &       0.279   &       0.279   &       0.279   &       0.279   \\
* p<0.05, ** p<0.01, *** p<0.001

. lpm_regs, lpm(r_lpm) estimator(regress) quietly
Dependent variable: r_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       
> reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &       
>  b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0034*  &      0.0034*  &      0.0034*  &      0.0034*  &      0.0043   &      0
> .0044   &      0.0043   &      0.0044   \\
                    &    (0.0014)   &    (0.0013)   &    (0.0014)   &    (0.0013)   &    (0.0023)   &    (0.
> 0023)   &    (0.0023)   &    (0.0023)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0127   &      0.0130   &      0.0129   &      0.0
> 132   &      0.0153   &      0.0156   &      0.0159   &      0.0161   \\
                    &    (0.0101)   &    (0.0101)   &    (0.0099)   &    (0.0100)   &    (0.0117)   &    (0.
> 0117)   &    (0.0115)   &    (0.0115)   \\
Phase 3 Clinical    &      0.0214   &      0.0211   &      0.0216   &      0.0213   &      0.0235   &      0
> .0232   &      0.0241   &      0.0237   \\
                    &    (0.0154)   &    (0.0153)   &    (0.0152)   &    (0.0151)   &    (0.0170)   &    (0.
> 0169)   &    (0.0169)   &    (0.0168)   \\
Trial site in US=1  &      0.0097***&      0.0089***&      0.0079** &      0.0070** &      0.0096***&      0
> .0086***&      0.0039   &      0.0029   \\
                    &    (0.0016)   &    (0.0016)   &    (0.0025)   &    (0.0024)   &    (0.0018)   &    (0.
> 0021)   &    (0.0026)   &    (0.0027)   \\
Drug indication for neoplasm=1&      0.1362***&      0.1364***&      0.1338***&      0.1339***&      0.1490*
> **&      0.1491***&      0.1417***&      0.1418***\\
                    &    (0.0140)   &    (0.0140)   &    (0.0111)   &    (0.0111)   &    (0.0176)   &    (0.
> 0176)   &    (0.0124)   &    (0.0124)   \\
Biomarker type: genomic=1&      0.2175   &      0.2176   &      0.2174   &      0.2174   &      0.2144   &  
>     0.2145   &      0.2138   &      0.2139   \\
                    &    (0.1086)   &    (0.1086)   &    (0.1087)   &    (0.1087)   &    (0.1110)   &    (0.
> 1109)   &    (0.1112)   &    (0.1112)   \\
Public firm (lower bound)&      0.0134*  &               &      0.0134*  &               &      0.0159*  &  
>              &      0.0159*  &               \\
                    &    (0.0054)   &               &    (0.0054)   &               &    (0.0072)   &       
>         &    (0.0072)   &               \\
Public firm (upper bound)&               &      0.0148*  &               &      0.0149*  &               &  
>     0.0166*  &               &      0.0166*  \\
                    &               &    (0.0058)   &               &    (0.0057)   &               &    (0.
> 0073)   &               &    (0.0073)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0052   & 
>      0.0054   &               &               &      0.0170   &      0.0170   \\
                    &               &               &    (0.0071)   &    (0.0071)   &               &       
>         &    (0.0125)   &    (0.0125)   \\
Constant            &     -6.8624*  &     -6.8852*  &     -6.8755*  &     -6.8987*  &     -8.8031   &     -8
> .9076   &     -8.7843   &     -8.8886   \\
                    &    (2.7860)   &    (2.7331)   &    (2.7727)   &    (2.7198)   &    (4.6997)   &    (4.
> 6847)   &    (4.7055)   &    (4.6907)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       
> 92568   &       92568   &       92568   \\
r2                  &       0.254   &       0.254   &       0.254   &       0.254   &       0.261   &       
> 0.262   &       0.262   &       0.262   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. * ------------------------------*
. * Duration regressions (Table 10)
. * ------------------------------*
. duration_regs, end_dates("actual") quietly
(7,269 observations deleted)
actual
(65,275 observations deleted)
Printing Table 10a

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       
> reg1f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &       
>  b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &      
>  0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &       
>   (.)   \\
Trial start year=2001&       5.675   &       6.033   &       6.835   &      -2.289   &      -2.086   &      
> -1.698   \\
                    &     (7.756)   &     (7.714)   &     (8.621)   &     (1.623)   &     (1.619)   &     (1
> .898)   \\
Trial start year=2002&      -5.284   &      -4.819   &      -3.938   &      -7.860***&      -7.290***&      
> -7.790***\\
                    &     (7.038)   &     (6.995)   &     (7.691)   &     (1.487)   &     (1.484)   &     (1
> .758)   \\
Trial start year=2003&     -11.644   &     -10.931   &      -9.152   &      -8.627***&      -7.957***&      
> -7.584***\\
                    &     (6.842)   &     (6.812)   &     (7.732)   &     (1.432)   &     (1.429)   &     (1
> .702)   \\
Trial start year=2004&     -11.085   &     -10.532   &      -7.281   &     -11.904***&     -11.266***&     -
> 10.399***\\
                    &     (6.628)   &     (6.595)   &     (7.535)   &     (1.364)   &     (1.363)   &     (1
> .612)   \\
Trial start year=2005&     -16.230*  &     -15.128*  &     -14.710*  &     -14.731***&     -13.921***&     -
> 13.363***\\
                    &     (6.502)   &     (6.480)   &     (7.343)   &     (1.334)   &     (1.333)   &     (1
> .564)   \\
Trial start year=2006&     -19.224** &     -18.319** &     -16.446*  &     -16.192***&     -15.398***&     -
> 14.291***\\
                    &     (6.346)   &     (6.322)   &     (7.007)   &     (1.313)   &     (1.313)   &     (1
> .541)   \\
Trial start year=2007&     -17.253** &     -16.380** &     -16.337*  &     -18.821***&     -17.919***&     -
> 17.635***\\
                    &     (6.211)   &     (6.183)   &     (6.816)   &     (1.300)   &     (1.300)   &     (1
> .521)   \\
Trial start year=2008&     -24.601***&     -23.623***&     -21.041** &     -19.564***&     -18.734***&     -
> 18.581***\\
                    &     (6.196)   &     (6.173)   &     (6.830)   &     (1.294)   &     (1.294)   &     (1
> .511)   \\
Trial start year=2009&     -24.544***&     -23.445***&     -22.338***&     -20.855***&     -20.063***&     -
> 20.412***\\
                    &     (6.106)   &     (6.080)   &     (6.717)   &     (1.287)   &     (1.287)   &     (1
> .501)   \\
Trial start year=2010&     -31.841***&     -30.671***&     -30.524***&     -22.228***&     -21.553***&     -
> 21.606***\\
                    &     (6.096)   &     (6.074)   &     (6.720)   &     (1.284)   &     (1.284)   &     (1
> .497)   \\
Trial start year=2011&     -33.317***&     -32.134***&     -30.927***&     -23.998***&     -23.315***&     -
> 23.664***\\
                    &     (6.041)   &     (6.015)   &     (6.627)   &     (1.278)   &     (1.278)   &     (1
> .486)   \\
Trial start year=2012&     -40.334***&     -39.112***&     -38.226***&     -25.287***&     -24.673***&     -
> 24.967***\\
                    &     (6.035)   &     (6.012)   &     (6.621)   &     (1.277)   &     (1.276)   &     (1
> .487)   \\
Trial start year=2013&     -45.876***&     -44.867***&     -43.180***&     -27.125***&     -26.510***&     -
> 27.558***\\
                    &     (6.036)   &     (6.007)   &     (6.627)   &     (1.273)   &     (1.273)   &     (1
> .478)   \\
Trial start year=2014&     -51.412***&     -49.984***&     -48.891***&     -30.222***&     -29.533***&     -
> 30.818***\\
                    &     (6.032)   &     (6.014)   &     (6.622)   &     (1.270)   &     (1.270)   &     (1
> .469)   \\
Trial start year=2015&     -57.012***&     -55.570***&     -54.440***&     -33.556***&     -32.788***&     -
> 34.798***\\
                    &     (6.049)   &     (6.033)   &     (6.658)   &     (1.270)   &     (1.271)   &     (1
> .472)   \\
Trial start year=2016&     -61.825***&     -60.082***&     -59.962***&     -35.674***&     -34.921***&     -
> 37.140***\\
                    &     (6.383)   &     (6.406)   &     (7.140)   &     (1.278)   &     (1.279)   &     (1
> .489)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       1.976   &       2.018   &       2.565   &       6.
> 472***&       6.192***&       5.374***\\
                    &     (1.048)   &     (1.045)   &     (1.359)   &     (0.224)   &     (0.223)   &     (0
> .339)   \\
Phase 3 Clinical    &      13.889***&      14.136***&      13.171***&       9.054***&       9.193***&       
> 6.859***\\
                    &     (1.566)   &     (1.555)   &     (2.063)   &     (0.254)   &     (0.252)   &     (0
> .400)   \\
Trial site in US    &       3.767***&       4.143***&               &       4.610***&       4.968***&       
>         \\
                    &     (0.958)   &     (0.962)   &               &     (0.188)   &     (0.188)   &       
>         \\
Drug indication for neoplasm&      13.258***&      13.335***&      12.781***&      19.608***&      19.403***
> &      18.488***\\
                    &     (1.283)   &     (1.275)   &     (1.750)   &     (0.269)   &     (0.268)   &     (0
> .375)   \\
Public firm (lower bound)&      -3.348***&               &               &      -6.620***&               &  
>              \\
                    &     (0.949)   &               &               &     (0.186)   &               &       
>         \\
Public firm (upper bound)&               &      -5.078***&      -6.021***&               &      -7.805***&  
>     -8.227***\\
                    &               &     (0.973)   &     (1.317)   &               &     (0.190)   &     (0
> .292)   \\
Constant            &      60.043***&      59.840***&      63.616***&      38.916***&      39.438***&      4
> 5.857***\\
                    &     (6.184)   &     (6.153)   &     (6.764)   &     (1.275)   &     (1.274)   &     (1
> .469)   \\
N                   &        2743   &        2743   &        1760   &       50186   &       50186   &       
> 26101   \\
r2                  &       0.330   &       0.334   &       0.320   &       0.304   &       0.311   &       
> 0.277   \\
* p<0.05, ** p<0.01, *** p<0.001
(43,741 observations deleted)
(0 real changes made)
Printing Table 10b

                    &       reg2a   &       reg2b   &       reg2c   &       reg2d   &       reg2e   &       
> reg2f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &       
>  b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &      
>  0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &       
>   (.)   \\
Trial start year=2001&       6.202   &       6.534   &       6.722   &       0.980   &       1.111   &      
>  0.315   \\
                    &     (8.054)   &     (8.014)   &     (7.890)   &     (2.295)   &     (2.293)   &     (2
> .309)   \\
Trial start year=2002&      -1.796   &      -1.390   &      -1.663   &      -2.458   &      -2.153   &      
> -2.395   \\
                    &     (7.389)   &     (7.347)   &     (7.291)   &     (2.144)   &     (2.143)   &     (2
> .178)   \\
Trial start year=2003&     -10.002   &      -9.370   &     -10.991   &      -5.336*  &      -4.865*  &      
> -5.773** \\
                    &     (7.242)   &     (7.214)   &     (7.157)   &     (2.077)   &     (2.076)   &     (2
> .095)   \\
Trial start year=2004&      -6.907   &      -6.450   &      -7.054   &      -7.276***&      -6.746***&      
> -8.244***\\
                    &     (7.051)   &     (7.017)   &     (6.941)   &     (1.984)   &     (1.983)   &     (2
> .007)   \\
Trial start year=2005&     -12.722   &     -11.905   &     -13.028   &     -10.437***&      -9.820***&     -
> 11.254***\\
                    &     (6.915)   &     (6.892)   &     (6.771)   &     (1.914)   &     (1.917)   &     (1
> .940)   \\
Trial start year=2006&     -15.142*  &     -14.415*  &     -15.465*  &     -11.022***&     -10.363***&     -
> 12.100***\\
                    &     (6.721)   &     (6.696)   &     (6.594)   &     (1.876)   &     (1.879)   &     (1
> .896)   \\
Trial start year=2007&     -13.012*  &     -12.266   &     -13.612*  &     -15.393***&     -14.656***&     -
> 16.478***\\
                    &     (6.580)   &     (6.553)   &     (6.472)   &     (1.850)   &     (1.855)   &     (1
> .877)   \\
Trial start year=2008&     -20.999** &     -20.145** &     -20.655** &     -16.307***&     -15.551***&     -
> 17.451***\\
                    &     (6.566)   &     (6.545)   &     (6.458)   &     (1.849)   &     (1.852)   &     (1
> .874)   \\
Trial start year=2009&     -21.463***&     -20.476** &     -21.251***&     -18.691***&     -17.829***&     -
> 20.003***\\
                    &     (6.475)   &     (6.449)   &     (6.371)   &     (1.825)   &     (1.830)   &     (1
> .860)   \\
Trial start year=2010&     -29.264***&     -28.293***&     -28.949***&     -22.018***&     -21.251***&     -
> 23.708***\\
                    &     (6.472)   &     (6.450)   &     (6.381)   &     (1.827)   &     (1.831)   &     (1
> .859)   \\
Trial start year=2011&     -29.902***&     -28.860***&     -29.719***&     -25.975***&     -25.199***&     -
> 27.716***\\
                    &     (6.406)   &     (6.380)   &     (6.303)   &     (1.817)   &     (1.820)   &     (1
> .859)   \\
Trial start year=2012&     -38.075***&     -37.032***&     -38.495***&     -29.404***&     -28.663***&     -
> 31.246***\\
                    &     (6.402)   &     (6.379)   &     (6.304)   &     (1.823)   &     (1.826)   &     (1
> .864)   \\
Trial start year=2013&     -44.612***&     -43.701***&     -44.780***&     -33.141***&     -32.200***&     -
> 35.343***\\
                    &     (6.408)   &     (6.379)   &     (6.296)   &     (1.815)   &     (1.816)   &     (1
> .854)   \\
Trial start year=2014&     -50.615***&     -49.422***&     -50.133***&     -40.322***&     -39.449***&     -
> 41.341***\\
                    &     (6.400)   &     (6.381)   &     (6.300)   &     (1.813)   &     (1.816)   &     (1
> .850)   \\
Trial start year=2015&     -57.509***&     -56.155***&     -56.221***&     -47.239***&     -46.571***&     -
> 47.896***\\
                    &     (6.428)   &     (6.420)   &     (6.341)   &     (1.815)   &     (1.814)   &     (1
> .859)   \\
Trial start year=2016&     -65.205***&     -63.720***&     -65.434***&     -49.785***&     -49.710***&     -
> 51.674***\\
                    &     (6.556)   &     (6.572)   &     (6.514)   &     (1.823)   &     (1.830)   &     (1
> .875)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       1.478   &       1.503   &       1.493   &       3.
> 120***&       3.049***&       2.974***\\
                    &     (1.129)   &     (1.127)   &     (1.142)   &     (0.484)   &     (0.484)   &     (0
> .517)   \\
Phase 3 Clinical    &      15.967***&      16.119***&      15.855***&      12.922***&      12.847***&      1
> 2.718***\\
                    &     (1.887)   &     (1.877)   &     (1.881)   &     (0.932)   &     (0.928)   &     (0
> .982)   \\
Trial site in US    &       3.902***&       4.208***&       4.375***&       3.946***&       4.209***&       
> 3.149***\\
                    &     (1.067)   &     (1.073)   &     (1.071)   &     (0.473)   &     (0.473)   &     (0
> .505)   \\
Public firm (lower bound)&      -2.993** &               &               &      -6.125***&               &  
>              \\
                    &     (1.052)   &               &               &     (0.467)   &               &       
>         \\
Public firm (upper bound)&               &      -4.447***&      -4.823***&               &      -6.703***&  
>     -6.957***\\
                    &               &     (1.074)   &     (1.088)   &               &     (0.460)   &     (0
> .486)   \\
Biomarker role (detailed): diagnosis&               &               &      -1.379   &               &       
>         &       2.303   \\
                    &               &               &     (3.120)   &               &               &     (1
> .343)   \\
Biomarker role (detailed): differential diagnosis&               &               &       6.741***&          
>      &               &       2.712*  \\
                    &               &               &     (1.542)   &               &               &     (1
> .203)   \\
Biomarker role (detailed): predicting drug resistance&               &               &       0.104   &      
>          &               &      -1.949   \\
                    &               &               &     (1.419)   &               &               &     (1
> .631)   \\
Biomarker role (detailed): predicting treatment efficacy&               &               &      -1.288   &   
>             &               &       4.413***\\
                    &               &               &     (3.371)   &               &               &     (1
> .287)   \\
Biomarker role (detailed): predicting treatment toxicity&               &               &      -3.182   &   
>             &               &       0.212   \\
                    &               &               &     (2.284)   &               &               &     (1
> .997)   \\
Biomarker role (detailed): screening&               &               &       0.560   &               &       
>         &       1.984   \\
                    &               &               &     (1.638)   &               &               &     (2
> .150)   \\
Biomarker role (detailed): selection for therapy&               &               &       3.233*  &           
>     &               &      -0.731   \\
                    &               &               &     (1.441)   &               &               &     (1
> .538)   \\
Biomarker role (detailed): disease profiling&               &               &       2.948   &               
> &               &       0.655   \\
                    &               &               &     (1.628)   &               &               &     (1
> .088)   \\
Biomarker role (detailed): monitoring disease progression&               &               &      -3.982*  &  
>              &               &      -1.286   \\
                    &               &               &     (1.728)   &               &               &     (1
> .711)   \\
Biomarker role (detailed): monitoring treatment efficacy&               &               &       1.745   &   
>             &               &       1.913   \\
                    &               &               &     (1.847)   &               &               &     (1
> .177)   \\
Biomarker role (detailed): monitoring treatment toxicity&               &               &      -7.350*  &   
>             &               &       2.222   \\
                    &               &               &     (3.068)   &               &               &     (2
> .757)   \\
Biomarker role (detailed): not determined&               &               &      -3.010   &               &  
>              &      -3.493   \\
                    &               &               &     (2.246)   &               &               &     (3
> .686)   \\
Biomarker role (detailed): prognosis&               &               &       0.007   &               &       
>         &      -0.777   \\
                    &               &               &     (2.162)   &               &               &     (1
> .298)   \\
Biomarker role (detailed): prognosis - risk stratification&               &               &       1.305   & 
>               &               &      -3.631   \\
                    &               &               &     (1.694)   &               &               &     (2
> .115)   \\
Biomarker role (detailed): risk factor&               &               &      -1.845   &               &     
>           &      -0.521   \\
                    &               &               &     (2.037)   &               &               &     (1
> .125)   \\
Biomarker role (detailed): staging&               &               &      -2.691   &               &         
>       &      -3.397*  \\
                    &               &               &     (1.566)   &               &               &     (1
> .370)   \\
Biomarker role (detailed): toxicity profiling&               &               &       0.000   &              
>  &               &       5.212   \\
                    &               &               &         (.)   &               &               &     (8
> .989)   \\
Constant            &      70.280***&      70.194***&      69.035***&      58.384***&      58.429***&      5
> 8.716***\\
                    &     (6.449)   &     (6.415)   &     (7.776)   &     (1.781)   &     (1.782)   &     (1
> .802)   \\
N                   &        2289   &        2289   &        2289   &       12423   &       12423   &       
> 11052   \\
r2                  &       0.303   &       0.306   &       0.321   &       0.192   &       0.195   &       
> 0.205   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. 
. log close
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/Projects/cortellis_projects/clinical_trials/reports/report_01-18-18
> /regs/regression_output_01-18-18.log
  log type:  text
 closed on:  18 Jan 2018, 10:13:46
------------------------------------------------------------------------------------------------------------
